Tuesday, July 11, 2017 7:25:02 AM
I am familiar with the tests that this device is being evaluated against as I am currently waiting for heart surgery and have had more ECG's than I can count on both hands , MRA test , Cardio Stress test and CTA which is done by injecting you with a dye then inserting a catheter containing wires through an artery into your heart in my case and taking x rays ,quite an unnerving procedure.
My personal belief is that this equipment is a complete game changer and for anyone who has not had the tests mentioned , some are easy to take some not so,such as the CTA . To be able to have a 2 minute non invasive test with instant results to determine the possibility of a stroke would offer a patient great peace of mind .
The recent results from Thomas Jefferson look promising to me as the subject is one that I am getting familiar with now due to researching my own condition. Also the tone of the statement reflects an upbeat positive position.
A major factor in the successful enrollment has been the ease at which CSS data can be acquired, which allows participants to have test studies performed quickly. We look forward to completing enrollment and having results to share.”
I'm no hardcore investor like some of you posting on this board but for me the amount of time that this has taken(first trial in 2005), the collaborations with leading companies, patent filings/applications and test results that can be seen thus far, to me represent a company that I can believe in and certainly hope will prove fruitful in the future.
I did not buy into CVR hoping to make a quick return as I believe this is a long term play of perhaps 2+ years(at least).
The worldwide potential for this is substantial. I am not worried that my investment has nearly halved at this point and I am certainly looking to increase my holdings as and when I can.
BTW have you noticed there is no detailed 32 page report available at the moment only the 2 page summary.
Sorry for a long winded first post. Good luck to all.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM